Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03292172
Title A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

ovarian cancer

triple-receptor negative breast cancer

Therapies

Atezolizumab + TEN-010

Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Oklahoma University Health Sciences Center Oklahoma City Oklahoma 73104 United States Details
Sarah Cannon Res Inst; TN Onc Nashville Tennessee 37203 United States Details
St Vincent's Hospital Sydney Darlinghurst New South Wales 2010 Australia Details
Peter MacCallum Cancer Centre; Medical Oncology Melbourne Victoria 3000 Australia Details
University Health Network; Princess Margaret Hospital; Medical Oncology Dept Toronto Ontario M5G 2M9 Canada Details
Rigshospitalet; Onkologisk Klinik København Ø 2100 Denmark Details
Western General Hospital Edinburgh EH4 2XU United Kingdom Details
Guys and St Thomas NHS Foundation Trust, Guys Hospital London SE1 9RT United Kingdom Details
The Christie Manchester M20 4BX United Kingdom Details
Churchill Hospital Oxford OX3 7LJ United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field